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ABSTRACT 
 
Our previous work with primary bovine fibroblasts demonstrated that quercetin, a 
potent mutagen found in high levels in bracken fern (Pteridium aquilinum), arrested 
cells in G1 and G2/M, in correlation with p53 activation. The expression of bovine 
papillomavirus type 4 (BPV-4) E7 overcame this arrest and lead to the development 
of tumourigenic cells lines (Beniston et al., 2001). Given the possible link between 
papillomavirus infection, bracken fern in the diet and cancer of the upper 
gastrointestinal (GI) tract in humans, we investigated whether a similar situation 
would occur in human cells transformed by human papillomavirus type 16 (HPV-16) 
oncoproteins. Quercetin arrested primary human foreskin keratinocytes in G1. Arrest 
was linked to an elevation of the cyclin dependent kinase inhibitor (cdki) p27Kip1. 
Expression of the HPV16 E6 and E7 oncoproteins in transformed cells failed to 
abrogate cell cycle arrest. G1 arrest in the transformed cells was also linked to an 
increase of p27Kip1 with a concomitant reduction of cyclin E associated kinase 
activity. This elevation of p27Kip1 was due not only to increased protein half-life, but 
also to increased mRNA transcription. 
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INTRODUCTION  
 
Human papillomaviruses are small DNA tumour viruses, which can infect mucosal 
and cutaneous epithelia, giving rise to benign hyperproliferative lesions. These lesions 
are under host immune surveillance and can regress spontaneously. Of the greater 
than 100 papillomaviruses now typed, roughly 30 types preferentially infect the 
mucosa of the anogenital tract. These HPVs can be grouped into high and low risk 
types. The high-risk types are those inducing lesions that can progress to squamous 
cell carcinoma. The rate of progression may be low, but nevertheless infection with 
high risk HPVs accounts for nearly all-human cervical cancers (for review see zur 
Hausen, 1996). The HPV types most commonly linked with genital cancer are 16 and 
18, and less frequently types 31, 33, 35 and 39. As well as genital cancer these high-
risk viruses have been linked to oropharyngeal carcinoma (Gillison et al., 2000) 
 
High risk HPV encode at least three different growth stimulating and transforming 
proteins: E5, E6 and E7. These proteins have an expanding number of cellular targets 
and functions (for review zur Hausen, 2000). E6 targets several tumour suppressor 
and anti-apoptotic proteins, perhaps the most important of which is p53 (Mantovani 
and Banks, 2001). These interactions cause the rapid degradation of the target proteins 
with consequent cell immortalisation. The E5 protein from HPV interacts with the 
16K subunit c protein in mammalian cells and yeast (Conrad et al., 1993, Ashby et al, 
2001) and, through this interaction, down-regulates gap junction intercellular 
communication (Oelze et al., 1995) and alters the acidification of endosomes (Straight 
et al., 1995) leading to continuous signalling from growth factors receptors. The E7 
oncoprotein has many roles (for review see Munger et al., 2001). One main function 
of E7 is to bind the pocket proteins causing the dissociation of the transcription factor 
E2F. Additionally E7 causes the destabilization of the p105Rb protein (Boyer et al., 
1996; Jones et al., 1997b) and interferes with the association between histone 
deacetylase and p105Rb (Brehm et al., 1998). Among the other cellular factors with 
which E7 is thought to interact are the cyclin dependent kinase inhibitors p21Waf1 and 
p27Kip1. These proteins are potent inhibitors of cyclin E and A complexes, and may be 
positive regulators of the cyclin D complexes (Sherr and Roberts, 1999 for review). 
E7 directly binds to p21Waf1 and inhibits both its effect on the cyclin/cdk complexes 
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and ability to inhibit DNA replication by binding PCNA (Jones et al., 1997a; Funk et 
al., 1997). The related cdki, p27Kip1, is also bound by E7, resulting in abrogation of 
the inhibitory activity on cyclin/cdk complexes (Zerfass-Thome et al., 1996). The 
combination of the HPV16 E6 and E7 oncoproteins has been shown to be sufficient to 
immortalise primary human keratinocytes (Hawley-Nelson et al., 1989).  
 
Progression of PV induced lesions to carcinoma requires co-factors. In the case of 
cervical carcinoma, some of the co-factors have been identified e.g. 
immunosuppression, smoking, oestrogen and progesterone (Dell and Gaston, 2001 
and references therein). A detailed study of the nature of the co-carcinogens and their 
interaction with papillomavirus has been conducted in cattle. Infection of the upper GI 
tract of cattle with BPV-4 causes benign papillomas. These papillomas can progress 
to carcinoma in cattle feeding on bracken fern. During progression, the Ha-ras 
oncogene becomes activated and the p53 gene undergoes mutations, highlighting the 
interaction between the mutagens present in the fern and the virus (Campo et al., 
1994). Quercetin is a potent mutagen widespread in nature but at its highest levels in 
bracken fern (Bjieldanes and Chang, 1977; Nakayasu et al., 1986). It causes oxidative 
DNA damage (Yamashita and Kawanishi, 2000), single strand DNA breaks (Fazal et 
al., 1990), DNA rearrangements (Suzuki et al., 1991) and chromosomal aberrations 
(Ishidate et al., 1988). Additionally quercetin interferes with several kinases (Jackson 
and Campo, 1995; Davies et al., 2000). In our in vitro experimental model of BPV-4 
associated oesophageal cancer, we found that quercetin could cause full oncogenic 
transformation of primary bovine fibroblasts partially transformed by BPV-4 and 
activated Ha-ras (Pennie and Campo, 1992; Cairney and Campo, 1995). This 
transformation was ascribed to the expression of BPV-4 E7 overcoming a quercetin-
induced G1 arrest mediated by p53, leading to the accumulation of mutations, 
including, as in vivo, mutations of the p53 gene (Beniston et al., 2001). 
 
HPV16 has been associated with up to 50% of oesophageal pre-cancers and cancers 
particularly in developing countries (Chang et al., 1990; Togawa et al., 1994; Suzuk 
et al., 1996; Cooper et al., 1995; de Villiers et al., 1999; Syrjanen, 2002). The highly 
variable geographical incidence of oesophageal cancer and of HPV detection in the 
cancer suggests a multi-factorial aetiology and the involvement of environmental 
dietary co-factors (Syrjanen, 2002). Some human populations are exposed to bracken 
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fern and this exposure has been linked epidemiologically to cancer of the upper GI 
tract in several parts of the developed and developing world (Galpain et al., 1990; 
Marliere et al., 2000; Alonso-Amelot et al., 1996; Hirayama, 1979; Villalobos-
Salazar et al., 1995). 
Given the possibility that papillomavirus infection and bracken fern are associated 
with oesophageal cancer in humans, as they are in cattle, and that quercetin promotes 
oncogenic transformation of BPV transformed cells, we decided to assay whether 
quercetin played a role in transformation of human keratinocytes by HPV.  
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MATERIALS AND METHODS 
 
Plasmids 
pCH110 carries the LacZ reporter gene driven by the SV40 early promoter 
(Pharmacia, Herefordshire, UK). pλ34-11 was a kind gift from Dr G. Sonenshein 
(Boston, USA) and has the human p27Kip1 promoter upstream of the firefly luciferase 
gene. pLXSN, pLXSN16E6, pLXSN16E7 and pLXSN16E6E7 are retroviral vectors 
containing the HPV16 E6, E7 or E6 and E7 genes (kind gift from Dr D.Galloway 
(Seattle, USA). 
 
Tissue Culture 
The retroviral vector constructs (pLXSN) were transfected in the packaging cell line 
Phoenix Ampho, cultured using DMEM supplemented with 10% foetal calf serum at 
37°C, 5%CO2 (Invitrogen Carlsbad, CA). 24 hours after transfection the supernatant 
was taken and cell debris was spun out. The virus containing supernatant was stored 
at -70°C until further use. Primary human foreskin keratinocytes (HFKs) (Bio-
Whittaker, Berks, UK) were routinely cultured in KGM-2 medium (Bio-Whittaker) at 
37°C, 5%CO2 being split 1 in 4 when 80-90% confluent. HFKE6/E7 were generated 
from HFKs being infected with recombinant retrovirus. To infect primary HFK cells 
24 hours before infection 2x105 cells were seeded into 25cm2 flasks with 5ml of 
media. 1.5ml of infection mix was overlaid on the cells for 6 hours at 37°C before 
being removed and replaced with 15ml of media. G418 selection of cells was started 
24 hours after infection at 500μg/ml for 14-21 days. Stable HFKE6/E7 cells were 
routinely cultured in KGM-2 medium (Bio-Whittaker) with the addition of 500μg/ml 
G418 (Invitrogen,) at 37°C, 5%CO2 and split 1 in 4 when 80-90% confluent. HaCaT 
cells were gown in DMEM without CaCl2, supplemented with 1mM Sodium Pyruvate 
and 2mM Glutamine and 10%FCS at 37°C, 5%CO2 and split 1 in 6 when 80-90% 
confluent. 
 
Cell proliferation was assayed by cell counts. HFKE6/E7 cells were seeded into 
100mm tissue culture plates (8x105/plate) and then left for 24 hours before being 
treated with 0, 5, 10 or 20μM quercetin. Cells were treated for 24, 48 or 72 hours, 
with new medium being added with fresh quercetin or EtOH every 24 hours. Cells 
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were trypsinzed, resuspended in 6ml of 5%FCS in PBS and counted in duplicate in a 
haemocytometer.  
 
Cell Cycle Analysis 
5x105 cells were plated into 100mm dishes and 24 hours later treated with 5, 10, 20 or 
50μM quercetin in EtOH (Sigma-Aldrich) for 36 hours. Control cells (0 μM) were 
treated with an equal volume of solvent (EtOH). Cells were trypsinised and 
centrifuged at 1000rpm at room temperature for 10 minutes. Supernatant was then 
removed before cells were resuspended in 0.5ml of IFA buffer (150mM Tris-HCl pH 
7.6, 500mM NaCl, 0.5% NaN3, 5% Foetal Calf Serum) and fixed with 70% EtOH. 
Fixed cells were stained using 20μg/ml propidium iodide (Sigma-Aldrich) and 
200μg/ml RNA-aseA (Kramel Biotech, Northumberland, UK), before being assayed 
on a Coulter Epics XL-MCL FACS machine.  
 
Immunoblotting and Immunoprecipitation 
Cells were seeded into 100mm dishes (5x105 per plate) and then left for 24 hours 
before being treated with 0, 5, 10 or 20μM quercetin. Cells were treated for 36 hours 
with new medium being added with fresh quercetin or EtOH after 24 hours, before 
being harvested. Cells were harvested in 100μl NP40 lysis buffer (0.1% NP40, 
150mM NaCl and 50mM Tris-HCl pH 7.6 with protease inhibitor cocktail (Roche, 
Mannheim, GER) per plate and scraped into eppendorf tubes on ice. Cells were lysed 
by being passed through an 18-gauge needle seven times and debris was pelleted by 
centrifugation at 14K rpm for 10 minutes at 4°C. Supernatant was then taken and 
assayed for protein concentration by the BCA method (Sigma-Aldrich) and stored at  
-20°C until use. 
 
For western blotting 25-100μg of cell lysate were first run on Tris-Glycine buffered 
SDS-PAGE gels utilising MOPS pH buffer (Invitrogen), before being transferred to 
nitrocellulose membrane for probing. Membranes were blocked in 5% Marvel milk in 
PBS for 1 hour at room temperature before being probed with the primary antibody 
for 1½ hours in 5% Marvel /PBS at room temperature. Membranes were washed three 
times for 10mins in PBS before the secondary antibody was added for 1 hour at room 
temperature in 5% Marvel/PBS. Membranes were again thoroughly washed in PBS 
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before being developed with ECL reagent (Amersham-Pharmacia, Bucks, UK). 
Primary Antibodies used were: p105Rb= IF8 (Santa Cruz, Santa Cruz, CA), p53= D0-
1 (Serotec), p21Waf1= Ab3 (Oncogene Research Products, La Jolla, CA), p27Kip1= 
Clone 57 (Transduction Laboratories, Heidelberg, GER), p16INK4a = DCS50 (Sigma-
Aldrich), β-Actin= AB1 (Oncogene Research Products), Skp2(p45)= N19 (Santa 
Cruz), Cyclin E= HE12 (Santa Cruz). Secondary Antibodies were anti mouse IgG-
HRP (Amersham-Pharmacia), anti mouse IgM-HRP and anti goat IgG-HRP (Santa 
Cruz). 
 
For immunoprecipitation 250μg of lysate was pre-cleared using 4μg of a non-specific 
mouse monoclonal antibody (Santa Cruz) and 100μl of Protein A-Sepharose beads 
(Sigma-Aldrich) for a total of 3 hours in a total volume of 500μl.  
Supernatants were collected and cyclin E was immunoprecipitated using 1μg of cyclin 
E antibody HE111 (Santa Cruz) for 1.5 hours before addition of 30μl of Protein A-
Sepharose beads. Lysates were incubated, with agitation, for a further 1.5 hours 
before the beads were pelleted and washed 3 times with ice-cold lysis buffer. 20μl of 
x2 sample buffer (100mM Tris-HCl pH 6.8, 4% SDS, 0.2% Bromophenol Blue, 20% 
Glycerol, 200mM DTT) was mixed with the beads. Beads were heated for 10 minutes 
at 70°C. Samples were then assayed by immunoblotting as above.  
 
Cyclin E Associated Kinase Assay 
Cells were seeded into 100mm dishes (5x105 per plate) and then left for 24 hours 
before being treated with 0, 5, 10 or 20μM quercetin. Cells were treated for 36 hours 
with new medium being added with fresh quercetin or EtOH after 24 hours, before 
being harvested. Cells were lysed in E/K2 activity lysis buffer (50mM Hepes pH7.5, 
150mM NaCl, 1% NP40, 2.5mM EGTA, 10mM NaF, 10mM β-Glycerophosphate, 
1mM Sodium Orthovanadate, 1mM DTT), by 3 freeze/thaw cycles. Lysate was spun 
at 14K rpm for 10 minutes to remove cell debris and the supernatant was assayed for 
protein concentration and stored at -70°C. 500μg of cell lysate were used per assay, 
and cyclin E was precipitated with 4μg of HE111 (Santa Cruz). Kinase activity was 
assayed by transfer of 32P to Histone H1 as substrate at 30°C for 30 minutes. 
Complexes were released from the beads by heating at 70°C for 10 minutes before 
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being run on a 10% Acrylamide SDS-PAGE gel, dried and exposed to film (Kodak, 
Rochester, NY). 
 
Reporter Gene Analysis 
2x105 HaCaT cells were plated into 60mm dishes 24 hours before transfection. Cells 
were transfected with 2μg of pλ34-11, or pGL3TK, and 2μg of pCH110 as a 
transfection efficiency control using Lipofectamine (Invitrogen) for 5 hours at 37°C, 
5%CO2 in serum free medium. Quercetin treatment started 24 hours after transfection 
with 0 to 50μM quercetin for 36 hours with fresh medium every 24 hours. Cells were 
harvested and assayed for luciferase activity with luciferase assay buffer (Promega, 
Madison, WI) in a Dynex-MLX luminometer. Protein concentration was determined 
by BCA assay (Sigma-Aldrich) and β-galactosidase activity was measured by colour 
conversion of ONPG (Sigma-Aldrich) monitored at 420nm.  
 
Real Time RT-PCR and Standard RT-PCR 
Total RNA was isolated from HFKE6/E7 cells using the RNeasy Minikit (Qiagen, 
Sussex, UK), and residual DNA was removed by DNA-aseI treatment according to 
the manufacturers guidelines (Invitrogen). Real time RT-PCR for p27Kip1, HPV16E7 
and β-Actin mRNA was carried out using the TaqmanÆ EZ RT-PCR Kit (Applied 
Biosystems, Foster City, CA) with gene specific primers and FAM/TAMRA probe 
designed by Primer Express v1.7 software. 10ng of RNA was used per reaction, with 
each condition being carried out in triplicate. For p27Kip1 primers were: p27FOR 5’-
CCGGTGGACCACGAAGAGT-3’ and p27REV 5’-GCTCGCCTCTTCCATGT 
CTC-3’ with probe 5’-AACCCGGGACTTGGAGAAGCACTGC-3’. For HPV16E7 
primers were: E7FOR 5’-AAGTGTGACTCTACGCTTCGGTT-3’ and E7REV 5’-
CATGTATAGTTGTTTGCAGCTCTGTG-3’ with probe  
5’-TGCGTACAAAGCACACACGTAGACATTCGTA-3’. For β-Actin the primers 
and probe were commercially available (Applied Biosystems). RT-PCR was 
performed using an ABI Prism 7700 Sequence detector. In each experiment additional 
reactions with 8 to 10 10-fold serial dilutions of template DNA were performed with 
each set of primers and probes on the same 96 well plates to generate standard curves. 
All samples were amplified in duplicate. The relative amounts of p27Kip1, HPV16E7 
or β-Actin mRNA were determined by using the standard curve method. Levels of 
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p27Kip1 and HPV16 E7 mRNA were normalised to β-Actin mRNA expression levels. 
Standards, β-Actin control samples and either p27Kip1 or HPV16 E7 test samples were 
analysed on the same 96 well plate for each individual experiment. 
In addition each RNA preparation used was tested for DNA contamination by using 
β-Actin primers and Taq polymerase instead of RT and Taq in standard RT-PCR 
reactions. Reverse transcription and subsequent PCR of 200ng of total RNA was 
carried out using gene specific primers with OneStep RT-PCR Kit (Qiagen) according 
to the manufacturers guidelines. β-actin mRNA was amplified using the primers:                              
ACTINFOR 5’-GCGTCTGGACCTGGCTGGCCGGGACCT-3’ and ACTINREV 5’-
GGAAGGCTGGAAGAGTGCCTCAGGGCAG-3’. HPV16 E6 and E7 mRNA was 
detected in expressing cell lines using standard RT-PCR reactions. The OneStep RT-
PCR Kit (Qiagen) was used according to the manufacturers guidelines with gene 
specific primers and 200ng of total RNA. As with the Real time RT-PCR DNA 
contamination was assayed by use of Taq polymerase instead of RT and Taq. HPV16 
E6 was amplified using the primers: E6 DETECT FOR: 5’ gcgacccagaaagttaccac 3’ 
and E6 DETECT REV: 5’ gcaacaagacatacatcgaccgg 3’. HPV16 E7 was amplified 
using the primers: E7 DETECT FOR: 5’ gcaaccagagacaactgatctc 3’ and E7 DETECT 
REV: 5’ tggggcacacaattcctagtg 3’. 
 
Cyclohexamide Analysis of protein half-life 
Protein half-life analysis of p27Kip1 in HFKE6/E7 cells was carried out using 
cyclohexamide (CHX) (Sigma-Aldrich). 5x105 cells were seeded in 100mm plates; 
then left for 24 hours before being treated with 0, 5, 10 or 20μM quercetin. Cells were 
treated for 36 hours, with new medium being added with fresh quercetin or EtOH 
after 24 hours, before being harvested. CHX in DMSO was added to a final 
concentration of 100μg/ml to each plate, DMSO only was used as a negative control. 
Cells were harvested in NP40 lysis buffer (see above) at regular time intervals after 
CHX/DMSO addition. Lysates were then run on Tris-Glycine buffered SDS-PAGE 
gels utilising MOPS pH buffer (Invitrogen), before being transferred to nitrocellulose 
membrane for probing for p27Kip1. Bands were then analysed by densitometry using a 
UMAX Powerlook III Flatbed scanner and ImageQuant v5.2 software. 
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RESULTS 
 
1. Quercetin induces cell cycle arrest in HFK cells. 
Previous work in the bovine system showed that quercetin was capable of arresting 
primary fibroblasts in both G1 and G2/M phases of the cell cycle. The expression of 
the BPV-4 E7 oncoprotein with activated Ha-ras was capable of overcoming the G1, 
but not the G2/M, arrest (Beniston et al., 2001). We reasoned that primary HFK cells 
might also undergo cell cycle arrest after quercetin exposure and that the HPV16 E6 
and E7 oncoproteins might be able to abrogate this arrest.  
 
Primary HFK cells were infected with a retrovirus expressing HPV16 E6 and/or E7. 
Cells were selected in G418 before being exposed to quercetin and assayed. To ensure 
that the HPV16 E6 and E7 oncogenes were expressed, RT-PCR was carried out to 
detect E6 and E7 mRNA. As a positive control two HaCaT cell clones expressing 
tagged versions of the oncoproteins were used. DNA Polymerase only (Taq) reactions 
without reverse transcriptase were carried out to detect contaminating DNA. Figure 
1A shows that both E6 and E7 are expressed in the HFK E6, E7 and E6/E7 cell lines. 
The reduction in p53 and p105Rb, the main targets of E6 and E7 respectively 
(Mantovani and Banks, 2001; Munger et al., 2001), confirmed the expression of the 
viral proteins (Figure 1B). 
Only the HFKE6/E7 cells will be discussed here. 
 
Primary HFK cells were exposed to 0 to 10μM quercetin for 36 hours, and HFKE6/E7 
cells up to 20μM. Cells were then fixed, stained with propidium iodide and assayed 
by FACS. Figure 2a shows that the primary HFK cells underwent a distinct increase 
in the G1 population after 36 hours with 5 or 10μM quercetin with a corresponding 
decrease in S and G2/M phases. Higher concentrations resulted in no further increase 
in the number of cells in G1 or decrease in the number of cells in G2/M (data not 
shown), leading to the conclusion that quercetin arrested the cells in G1. HFKE6/E7 
transformed cells displayed an equivalent response to quercetin with an increase in G1 
and decrease in S phase (figure 2b). Untreated HFKE6/E7 cells continued to expand 
over 72 hours whereas quercetin treated HFKE6/E7 cells stopped proliferating (figure 
2c). This showed that the cells were in fact arresting and not simply proliferating 
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more slowly. Hence we can conclude that both primary and E6/E7 transformed 
human keratinocytes arrest in G1 upon quercetin treatment.  
 
2. p27Kip1 is elevated in HFK and HFKE6/E7 cells upon quercetin exposure. 
Earlier work had linked quercetin exposure to p53 elevation with an increase in 
p21Waf1 (Plaumann et al., 1996; Beniston et al., 2001), therefore both p53 and p21 Waf1 
levels were assayed by immunoblotting. In addition as quercetin caused G1 arrest in 
HFKE6/E7 two other cdk inhibitors associated with G1 cell cycle arrest, p16INK4a and 
p27Kip1, were also examined. Figure 3a shows that in primary HFKs p53 was only 
slightly elevated following quercetin exposure of 5 to 20μM. However the increase in 
p53 protein levels did not correlate to an increase of p21Waf1 expression, and there was 
a noticeable decrease in the level of p21Waf1at 20μM quercetin. At 50μM quercetin 
p53 protein levels raised still further, while p21Waf1 levels dropped below the level of 
detection (data not shown). The related cdki p27Kip1 however increased at 5 to 20μM 
quercetin, suggesting that p27Kip1 mediated the G1 arrest. HFKE6/E7 cells showed no 
change in p53 and p21Waf1 levels in response to quercetin, with the exception of a 
decrease in p21Waf1 levels at 20μM quercetin (figure 3b). In HFKE6/E7cells, as in 
primary cells, p27Kip1 increased with quercetin exposure up to 20μM, again 
suggesting its role in G1 arrest. Additionally in both primary and E6/E7 transformed 
HFK cells p16INK4a decreased with quercetin exposure indicating that this cdk4 
inhibitor is unlikely to play an important role in quercetin induced G1 arrest in these 
cells. These changes in cell cycle regulators following quercetin treatment were 
consistently observed over at least three experiments. 
 
3. Quercetin causes an increase in p27Kip1 protein half-life 
In agreement with the increase in the p27Kip1 protein, quercetin caused an increase in 
the half-life of p27Kip1 protein. HFKE6/E7 cells treated with DMSO only after 36 
hours of 0μM quercetin treatment showed a continuous elevation of p27Kip1, whereas 
cells treated with 100μg/ml cyclohexamide (in DMSO) displayed a reduction in 
p27Kip1 protein levels over 24 hours (top two rows, figure 4a). This demonstrated that 
the cyclohexamide treatment was successful in inhibiting protein translation. Cells 
treated with 5-20μM quercetin for 36 hours and with cyclohexamide, displayed an 
increase in p27Kip1 half-life. Protein bands were analysed by densitometry and data 
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were normalised to the 0 hour time point. After 36 hours of 0μM quercetin p27Kip1 
half-life was calculated to be approximately 1.5 hours, whereas after treatment with 
5μM quercetin, p27Kip1 half-life was approximately 4 hours. After treatment with 10 
or 20μM quercetin, p27Kip1 half-life was as long as 24 hours (figure 4a). A half-life of 
1.5 hours in normally cycling cells seemed high as p27Kip1 half-life has been predicted 
to be in the region of around 30 to 40 minutes (Reinstein et al., 2000). However 
E6/E7 transformed cells do have a constitutively higher level of  p27 Kip1 expression 
than primary cells (figure 4b) indicating some degree of base level activation. Indeed 
it has been observed that p27Kip1 levels are elevated in cervical lesions (Zehbe et al., 
1999).  
 
To further investigate p27Kip1 half-life in quercetin treated HFK E6/E7 cells 
Skp2(p45) levels were assayed by western blot analysis. Skp2(p45) is the F-box 
protein, which specifically recognises p27Kip1 (Carrano et al., 1999; Malek et al., 
2001) and recruits it to the SCF core complex, thus promoting its ubiquitination and 
degradation, although there are suggestions that a Skp2(p45)-independend 
degradation of p27Kip1 in G1 exists (Hara et al., 2001). Analysis of Skp2(p45) levels 
in HFKE6/E7 showed that Skp2(p45) levels decreased as the concentration of 
quercetin increased (figure 4c). This effect is unlikely to be due to alterations in 
Skp2(p45) levels during the cell cycle, as in normally cycling cells Skp2(p45) is low 
in early/mid G1 and high in late G1, concomitant with the normal decrease in p27Kip1 
protein. 
 
4. Reduction in Cyclin E levels and increased association of p27Kip1 with Cyclin E 
correlate with decreased Cyclin E associated kinase activity 
As quercetin treatment elevated p27Kip1 protein levels and increased the protein’s half-
life, it was hypothesized that the cause of the G1 arrest in the cells was due to the 
activation of the cdki. To confirm this, cyclin E-associated kinase (E/K2) assays were 
carried out. Cyclin E was immunoprecipitated and activity was assayed by transfer of 
32P to Histone H1. Non-specific IgG control immunoprecipitations showed no 
associated kinase activity (data not shown). Figure 5a shows that control cells had a 
detectable E/K2 activity, whereas quercetin significantly decreased or completely 
abolished E/K2 activity even at 5μM. Cyclin E was immunoprecipitated under 
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identical conditions and immunoblotting revealed that its amount was approximately 
constant up to 10 μM quercetin (Figure 5a). The observation was supported by 
separate western blot analysis (figure 5b). The initial increase of cyclin E with 5μM 
quercetin seen during immunoprecipitations (figure 5a) was not observed consistently 
(figure 5b).  
 
To determine whether the loss of E/K2 activity was due to inhibition by p27Kip1, 
membranes were stripped and re-probed for p27Kip1. As can be seen in figure 5a the 
level of p27Kip1 associated with cyclin E increased with increasing quercetin 
concentration. We interpret these results as an indication that quercetin raised the 
p27Kip1 level associated with cyclin E , and this abolished cyclin E-associated kinase 
activity.  
 
5. Quercetin treatment activates the p27Kip1 promoter and results in increased 
mRNA levels 
A key control method for p27Kip1 is post translation control through its half-life 
(Lloyd et al., 1999; Nakayama et al., 2001 for reviews). However other methods of 
control may also play a part. To examine possible transcriptional control we used the 
human p27Kip1 promoter directing the transcription of the firefly luciferase gene 
(pλ34-11). The plasmid was transfected into HaCaT cells, which then were treated for 
36 hours with 0 to 20μM quercetin before being harvested. Transfection efficiency 
was checked by co-transfection with the pCH110 β-galactosidase plasmid. Quercetin 
had no effect on expression of β-galactosidase from the SV40 promoter (data not 
shown). Figure 6 shows the average of 4 transcription assays each done in duplicate, 
expressed as fold activation over control. The activity of the p27Kip1 promoter 
increased significantly with increasing quercetin concentrations, from 3 fold at 5μM 
to 6 fold at 20μM quercetin. Higher quercetin concentrations did not result in further 
increase of the p27Kip1 promoter activity (data not shown). The pGL3TK plasmid in 
which the tk promoter directs expression of luciferase (Vance et al., 1999) was used 
as a control to examine whether any possible effect observed was specific for the 
p27Kip1 promoter or common to other promoters.  There was no significant increase in 
the transcriptional activity of the tk promoter with increasing quercetin concentration 
(figure 6). These results indicate that quercetin-dependent trans-activation of the 
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p27Kip1 gene promoter acts via one or more elements specific to the promoter, and not 
on components of the basic transcription machinery.  
 
Real-time RT-PCR was carried out to assay whether the increase in transcription 
activity of the p27 promoter resulted in elevated levels of p27Kip1mRNA. Figure 7a 
shows the average of 4 individual experiments each consisting of triplicate samples. 
The results confirmed that quercetin exposure did increase the level of p27Kip1mRNA 
in HFKE6/E7 by approximately 3 fold at 20μM quercetin. 
 
6. Quercetin treatment results in no alteration in HPV16 E7 mRNA levels  
Another key factor in the arrest of the HFKE6/E7 cells could be not only the elevation 
of the cdki p27Kip1, but also the reduction of the viral oncoprotein hypothesized to 
abrogate its function i.e. E7. As attempts to detect E7 in the HFKE6/E7 cells by 
immunoblotting were unsuccessful with available antibodies, a more indirect 
assessment method had to be undertaken. Real time RT-PCR was carried out to 
determine whether quercetin treatment of these cells had any impact upon E7 mRNA 
levels. Figure 7b shows the average of four independent experiments each consisting 
of triplicate samples. Quercetin treatment resulted in no significant alteration in E7 
mRNA levels. This would indicate that there is no variation in the level of HPV16E7 
due to quercetin exposure. 
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DISCUSSION 
 
Considerable evidence points to a possible co-operation or synergy between HPV 
infection and bracken fern in carcinogenesis of the upper GI tract in humans, as 
reported in cattle. People exposed to bracken fern, whether as spores or in the diet, are 
at greater risk of developing oesophageal and gastric carcinoma (Galpain et al., 1990; 
Marliere et al., 2000; Alonso-Amelot et al., 1996; Hirayama, 1979 and Villalobos-
Salazar et al., 1995; Alonso-Amelot and Avendano, 2001). Moreover HPV-16 has 
been found in up to approximately 50% of oesophageal cancers and pre-cancers in 
developing countries  (Chang et al., 1990; Togawa et al., 1994; Suzuk et a., 1996; 
Cooper et al., 1995; de Villiers et al., 1999; Syrjanen, 2002). There is a geographical 
overlap between consumption of bracken fern, infection of the alimentary canal 
mucosa by HPV and upper GI tract cancer particularly in Asia and South America.   
 
Our study aimed to determine whether quercetin treatment would cause cell cycle 
arrest in primary human keratinocytes, the natural host of HPV, as it does in a large 
variety of primary and transformed cell lines (Beniston et al., 2001; Casagrande and 
Darbon, 2001; Choi et al., 2001; Plaumann et al., 1996). We hypothesised that 
expression of the HPV16 E6 and E7 oncogenes would abrogate the quercetin-induced 
cell cycle arrest thereby leading, as in the bovine model, to inheritable genetic 
alterations, the accumulation of which, together with the action of the viral 
oncoproteins, would increase the risk of full transformation of the cell. 
 
Quercetin arrested both HFK and HFKE6/E7 cells in the G1 phase of the cell cycle. 
The data presented do not conclusively prove or disprove a G2/M arrest in either cell 
type in response to quercetin, and further investigation is yet to be done. Hence here 
we have concentrated on the molecular mechanisms of the G1 arrest. In bovine cells 
quercetin caused elevation of both p53 and p21Waf1, however in the HFKE6/E7 cells 
there was no p53 response over the full range of quercetin concentrations, though this 
may be due in part to E6-mediated degradation of p53. HFK cells did demonstrate a 
modest  increase in p53 levels at high quercetin concentration, but in these conditions, 
a number of cell cycle regulators were noticeably decreased or absent, possibly due to 
apoptosis induced by quercetin (Yamashita and Kawanishi, 2000; Rong et al., 2000; 
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Iwashita et al., 2000). These observations make it unlikely that p53 or p21Waf1 play a 
necessary role in quercetin-induced G1 arrest in HFK cells.  
 
Expression of E7 has been shown to overcome the effects of high levels of p16INK4a, a 
member of the INK4 family of cdki (Martin et al., 1998), and high expression of 
p16INK4a has been correlated to E7 expression in cervical cancer samples (Sano et al., 
2002). Quercetin treatment lead to a reduction of p16INK4a levels in both HFK and 
HFKE6/E7 cells, strongly indicating that p16INK4a is unlikely to be the cause of the 
observed G1 arrest. 
 
Quercetin caused a dose dependent increase in p27Kip1 levels in both primary and 
transformed cells. This was due to an increase in transcriptional activity of the p27Kip1 
gene and the concomitant increase in mRNA. In addition the half-life of the protein 
increased too and this was accompanied by the reduction of the F box protein 
Skp2(p45) that promotes the turnover of p27Kip1 (Carrano et al., 1999). Increasing 
quercetin concentrations lead to increased association of p27Kip1 with cyclin E and a 
corresponding decrease in cyclin E-associated kinase activity. Altogether these 
observations provide evidence that quercetin causes G1 arrest in HFK and HFKE6/E7 
cells through p27Kip1. 
 
HPV16E7 has been reported to bind directly to, and inhibit both p21Waf1 and p27Kip1 
(Funk et al., 1997; Jones et al., 1997a; Zerfass-Thome et al., 1996). Additionally high 
levels of p21Waf1 and p27Kip1 have been found in cervical samples containing HPV16 
(Zehbe et al., 1999). While our study does not examine the effect of E7 on p21Waf1, it 
is interesting that in HFKE6/E7 cells p27Kip1 is the most likely cause of G1 arrest 
upon quercetin exposure. In agreement with others we noted an increased expression 
of p27Kip1 in HFKE6/E7 cells (figure 4b). This high level of p27Kip1 may be tolerated 
by the E7-expressing cells causing a significant level of cdk2 activity to be retained. 
Upon quercetin treatment however the amount of p27Kip1 raises still further and 
possible alterations in post-translational modification of p27Kip1 could promote an 
inhibitory role on cell cycle progression, such as alleviation of PKB phosphorylation 
(Liang et al., 2002).  
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The failure of HFK16E6/E7 cells to overcome quercetin-induced G1-arrest does not 
disprove the role of either HPV or bracken fern in the aetiology of human 
oesophageal carcinoma. There are several reasons to account for the different 
outcome of quercetin treatment of PV-transformed bovine and human cells: bovine 
fibroblasts may intrinsically respond to quercetin differently from human 
keratinocytes. This would be supported by the observation that quercetin induces both 
p53 and p21Waf1 in bovine fibroblasts (Beniston et al., 2001) but p27Kip1 in HFK 
(Figure 3). Moreover, the major difference between our bovine and human in vitro 
systems is the absence of activated Ha-ras in the HFKE6/E7 cells. Activated Ha-ras, 
seen in BPV-4 associated carcinoma, was required for immortalisation of BPV-4 
transformed cells, due to the lack of the E6 gene in BPV-4 (Jackson et al., 1991).  
Members of the ras gene family are often over-expressed or amplified (Galiana et al., 
1995; Sorsdahl et al., 1994) in human oesophageal cancers, implicating the ras 
proteins in oesophageal carcinogenesis, although activating point mutations are rare 
(Arber et al., 2000; Casson et al., 1997). It would be informative to ascertain what 
effects quercetin would have in HFKE6/E7 overexpressing ras. Furthermore, bracken 
fern contains numerous mutagens and carcinogens in addition to quercetin, including 
the sesquiterpene ptaquiloside. Ptaquiloside has been shown to be one of the active 
chemicals in bracken fern in Salmonella and in rats (Matoba et al., 1987; Hirono et 
al., 1987; Potter and Baird, 2000). It will be important to test ptaquiloside in 
HFK16E6/E7 cells. 
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FIGURE LEGENDS 
 
Figure 1: A, Detection of E6 and E7 in established cell lines. Gene Specific RT-PCR 
was carried out for HPV16E6 (lanes 1-7) and HPV16E7 (lanes 8-14). Vector only 
(lanes 1, 4, 8 &11), pLXSNE6 (lane 2 & 5), pLXSNE7 (lane 9 &12), pLXSNE6/E7 
(lane 3,6, 10 & 13). HaCaT HAE6 cell line RNA was positive control for E6 (lane 7) 
and HaCaT FLAGE7 cell line RNA was positive control for E7 (lane 14). DNA 
contamination controls were reactions using Taq only (lanes 4-6 & 11-13). B, 
reduction in p53 and p105Rb protein levels in HFKE6/E7. membranes were probed 
with D0-1 for p53 and IF8 for p105Rb (top row) and AB1 for β-Actin (bottom row).. 
 
Figure 2: Cell cycle profiles of primary and transformed cells. Cells were grown in 0 
to 10 or 20μM quercetin for up to 36 hours. (A) Histograms show the differences in 
cell cycle phases between control cells grown in EtOH and cells grown in quercetin. 
Representative cell cycle profiles of primary HFK cells grown in 0, 5 or 10μM 
quercetin for 36 hours are shown. (B) Representative cell cycle profiles of HFK 
E6/E7 cells grown in 0, 5, 10 or 20μM quercetin for 36 hours are shown. Percentage 
population of cells stated under graphs were determined using PI staining by Expo 32 
Multicomp software. (C) Cell proliferation assay. HFKE6/E7 cells were treated with 0 
to 20μM quercetin up to 72 hours before being trypsinized and counted. The 
experiment was repeated three times and the average number of cells is shown with 
error bars (SD). 
 
Figure 3: p27Kip1 protein is elevated in response to quercetin exposure in (A) primary 
HFK and (B) HFKE6/E7 cells. Cells were treated with 0 to 20μM quercetin for 36 
hours before harvesting. Membranes were probed for p53 (top tow), p21Waf1 (second 
row), p27Kip1 (third row), p16INK4a (fourth row) and β-Actin used as a loading control 
(bottom row). The experiment was repeated three times at least with identical results. 
 
Figure 4: p27Kip1 protein half-life is elevated in response to quercetin exposure in 
HFK E6/E7. (A) Cells were treated with 0μΜ quercetin for 36 hours before being 
treated with 100μg/ml cyclohexamide (CHX) or DMSO control for up to 24 hours. 
Samples were immunoblotted and membranes were probed for p27Kip1 (upper two 
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panels) to ensure CHX activity. Immunoblot assay of HFKE6E7 cells treated with 0 
to 20μΜ quercetin for 36 hours then 100μg/ml CHX for up to 24 hours. Samples were 
immunoblotted and membranes were probed for p27Kip1 (lower four panels). 
Densitometry was carried out on bands, normalised to protein levels at time point 0 
hour, and shown by graphical representation. (B) Comparison of p27Kip1 levels in both 
primary and HFKE6E7 cells. Cells were treated with 0,5 or 20μM quercetin for 36 
hours before harvesting. Membranes were probed for p27Kip1 (top row) with Actin 
used as a loading control (bottom row). (C) Immunoblot assay of Skp2 (p45) protein 
levels (top row) with actin as a loading control (bottom row). Cells were treated with 
0 to 20μM quercetin for 36 hours before harvesting. 
 
 
Figure 5: Quercetin reduces cyclin E associated kinase activity in HFKE6/E7 cells. 
Cells were treated with 0 to 10μM quercetin for 36 hours before harvesting. (A) 
Cyclin E associated kinase activity was determined by radiolabelling of histone H1 by 
phosphorylation (top). Cyclin E immunoprecipitation was carried out in parallel as a 
loading control (middle). Membrane was then re-probed for p27Kip1 (bottom row). (B) 
Membranes were probed for Cyclin E (top tow) with Actin used as a loading control 
(bottom row).  
 
Figure 6: Quercetin increases transcription from the p27Kip1 promoter. Cells were 
transfected with 2μg of either pλ34-11 (human p27Kip1 promoter reporter) or pGL3TK 
(TK basal promoter reporter) together with 2μg of pCH110 (constitutive β-
galactosidase expression construct) as a control for transfection efficiency. Cells were 
then treated with 0 to 20μM quercetin for 36 hours. Luciferase activity was 
normalized to β-galactosidase specific activity. Results are shown as fold induction 
over control treatment (0μM). 
 
Figure 7: A. Quercetin elevates p27Kip1 mRNA levels. Cells were treated with 0 to 
20μM quercetin for 36 hours before total RNA was extracted. Real Time RT-PCR 
was carried out to determine p27Kip1 mRNA levels and were normalised to β-Actin 
mRNA levels as a loading control. Results are shown as fold increase over 0μM 
quercetin. B. Quercetin does not affect HPV16E7 mRNA levels. Cells were treated 
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with 0 to 10μM quercetin for 36 hours before total RNA was extracted. Real Time 
RT-PCR was carried out to determine HPV16E7 mRNA levels and were normalised 
to β-Actin mRNA levels as a loading control. Results are shown as fold change over 
0μM quercetin. 
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